ArticleCureus2025
Survival Impact of Neoadjuvant Chemotherapy With Bevacizumab Followed by Radical Hysterectomy for Locally Advanced Cervical Cancer With Lymph Node Metastasis: Insights From a Single-Institution Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the therapeutic efficacy of neoadjuvant chemotherapy (NAC) with bevacizumab prior to radical hysterectomy in locally advanced cervical cancer with lymph node metastasis.
methodsThis single-institution, retrospective study was conducted at Kumamoto University Hospital (Kumamoto, JPN). The medical records of six consecutive patients with stage IIIC cervical cancer who received NAC with bevacizumab followed by radical hysterectomy were reviewed. Patients were treated between January 2022 and January 2024, with follow-up continuing through April 2025. Treatment responses, survival outcomes, and perioperative outcomes, including surgical complications and adverse events, were analyzed.
resultsAll six patients had tumors ≥4 cm with parametrial invasion (T2b); two had stage IIIC1r and four had IIIC2r disease. All patients completed three to four cycles of platinum-based NAC with bevacizumab and subsequently underwent radical surgery. Substantial tumor regression after NAC was observed in all cases, and notably, pathological complete response was achieved in three patients (50.0%). At a median follow-up of 25.5 months, five patients (83.3%) remained recurrence-free, and no deaths had occurred. One patient with pelvic nodal recurrence underwent complete resection followed by concurrent chemoradiotherapy, achieving sustained disease-free status. All surgeries were completed without severe perioperative complications. No severe bevacizumab-related adverse events were observed.
conclusionThe NAC with bevacizumab followed by radical hysterectomy was feasible, well tolerated, and demonstrated promising efficacy in patients with locally advanced cervical cancer accompanied by lymph node metastasis. This strategy demonstrated remarkably high clinical response and survival outcomes, along with favorable perioperative safety, supporting its potential as a multimodal treatment option for selected high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.